Biotech IV Monitor

CRNX — Crinetics Pharmaceuticals Inc.

$8.8B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Crinetics Pharmaceuticals Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is May 2027.

Next readoutMay 2027in ~6 months
Upcoming readouts53 Phase 3
Market cap$8.8B

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 1/2 atumelnant
Cushing Syndrome; Cushing Disease · NCT05804669
August 2026
Primary data collected

Upcoming readouts

Phase 3 Atumelnant
Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia · NCT07144163
May 2027
Recruiting
Phase 3 Paltusotine
Carcinoid Syndrome; Carcinoid · NCT07087054
August 2027
Ongoing
Phase 1/2 CRN09682
SST2-positive Neuroendocrine Neoplasms; Neuroendocrine Tumors · NCT07129252
August 2027
Ongoing
Phase 2 atumelnant (CRN04894)
Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia · NCT06712823
July 2029
Recruiting
Phase 2/3 Atumelnant
Congenital Adrenal Hyperplasia; Classic Congenital Adrenal Hyperplasia · NCT07159841
March 2030
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow CRNX, you can start the conversation.
Track CRNX in real time
See live implied volatility for CRNX and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on CRNX
Contact — questions or corrections about CRNX: dukeupt@gmail.com